Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M et al. Cancer Lett. 2015 Jun 23. pii: S0304-3835(15)00403-6. doi: 10.1016/j.canlet.2015.06.011. [Epub ahead of print].

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Kandela I et al. Elife. 2015 Jun 25;4. doi: 10.7554/eLife.07072.

KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.
Riz I et al. Oncotarget. 2015 Jun 19. [Epub ahead of print].

Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
Jagannathan S et al. Leukemia. 2015 Jun 25. doi: 10.1038/leu.2015.157. [Epub ahead of print].

Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients.
Pojero F et al. Immun Ageing. 2015 Jun 4;12:5. doi: 10.1186/s12979-015-0032-1. eCollection 2015.

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J et al. Cancer Chemother Pharmacol. 2015 Jun 23. [Epub ahead of print].

Type 2 diabetes-related variants influence the risk of developing multiple myeloma.
Rios R et al. Endocr Relat Cancer. 2015 Jun 22. pii: ERC-15-0029. [Epub ahead of print].

Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.
Ménager J et al. PLoS One. 2015 Jun 22;10(6):e0130249. doi: 10.1371/journal.pone.0130249. eCollection 2015.

Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.
Aouali N et al. PLoS One. 2015 Jun 19;10(6):e0130339. doi: 10.1371/journal.pone.0130339. eCollection 2015.

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M et al. Oncotarget. 2015 Jun 10. [Epub ahead of print].

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.
Yousef S et al. J Transl Med. 2015 Jun 20;13:197. doi: 10.1186/s12967-015-0562-5.

Insulin Effects on Survival of Human Multiple Myeloma Cells.
Shushanov SS et al. Bull Exp Biol Med. 2015 Jun 20. [Epub ahead of print].

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.
Holien T et al. Oncotarget. 2015 Jun 2. [Epub ahead of print].

PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/β-catenin/BCL-9 signaling pathway.
Xu Y et al. Oncol Rep. 2015 Jun 11. doi: 10.3892/or.2015.4056. [Epub ahead of print].

Association between the MTHFR C677T polymorphism and risk of cancer: evidence from 446 case-control studies.
Xie SZ et al. Tumour Biol. 2015 Jun 17. [Epub ahead of print].

Cancer Risk Following Pernicious Anemia in the US Elderly Population.
Murphy G et al. Clin Gastroenterol Hepatol. 2015 Jun 12. pii: S1542-3565(15)00790-9. doi: 10.1016/j.cgh.2015.05.040. [Epub ahead of print].

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Guillerey C et al. J Clin Invest. 2015 Jun 15. pii: 82646. doi: 10.1172/JCI82646. [Epub ahead of print].

17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
Lee J et al. Hematol Oncol. 2015 Jun 15. doi: 10.1002/hon.2208. [Epub ahead of print].

Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6.
Kong FC et al. J Huazhong Univ Sci Technolog Med Sci. 2015 Jun;35(3):343-9. doi: 10.1007/s11596-015-1435-0. Epub 2015 Jun 14.

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands inMultiple Myeloma Cells.
Zingoni A et al. J Immunol. 2015 Jun 12. pii: 1402643. [Epub ahead of print].

Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A et al. Expert Rev Hematol. 2015 Jun 12:1-11. [Epub ahead of print].

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M et al. Haematologica. 2015 Jun 11. pii: haematol.2014.109421. [Epub ahead of print].

Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies.
Dalamaga M et al. Horm Mol Biol Clin Investig. 2015 Jun 9. pii: /j/hmbci.ahead-of-print/hmbci-2015-0016/hmbci-2015-0016.xml. doi: 10.1515/hmbci-2015-0016. [Epub ahead of print].

Single-molecule analysis reveals widespread structural variation in multiple myeloma.
Gupta A et al. Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7689-94. doi: 10.1073/pnas.1418577112. Epub 2015 Jun 8.

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.
Olsen OE et al. Cell Commun Signal. 2015 Jun 6;13(1):27. doi: 10.1186/s12964-015-0104-z.

Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells.
Ashihara E et al. Biochem Biophys Res Commun. 2015 Jun 3. pii: S0006-291X(15)30042-5. doi: 10.1016/j.bbrc.2015.05.118. [Epub ahead of print].

A Plastic SQSTM1/p62-Dependent Autophagic Reserve Maintains Proteostasis and Determines Proteasome Inhibitor Susceptibility in Multiple Myeloma Cells.
Milan E et al. Autophagy. 2015 Jun 4:0. [Epub ahead of print].

Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma.
Aref S et al. Hematol Oncol. 2015 Jun 1. doi: 10.1002/hon.2206. [Epub ahead of print].

Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma.
Peng J et al. Tumour Biol. 2015 Jun 2. [Epub ahead of print].

The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma
Sponaas AM et al. Immun Inflamm Dis. 2015 Jun;3(2):94-102. doi: 10.1002/iid3.53. Epub 2015 Mar 2.

High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.
Devetzoglou M et al. Tumour Biol. 2015 May 31. [Epub ahead of print].

Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.
Adomako A et al. BMC Cancer. 2015 May 30;15:444. doi: 10.1186/s12885-015-1460-1.

Evaluation of Pharmacokinetic and Pharmacodynamic Interactions when Lenalidomide is Co-administered with Warfarin in a Randomized Clinical Trial Setting.
Weiss D et al. Clin Drug Investig. 2015 May 30. [Epub ahead of print].

A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.
Kim SY et al. Blood Cancer J. 2015 May 29;5:e316. doi: 10.1038/bcj.2015.39.

Meta-analysis of the association of MTHFR polymorphisms with multiple myeloma risk.
Ma LM et al. Sci Rep. 2015 May 29;5:10735. doi: 10.1038/srep10735.